Next-generation prostate-specific antigen test: precursor form of prostate-specific antigen

Area of Science:

• Urology
• Oncology
• Biochemistry

Background:

• Current prostate-specific antigen (PSA) screening faces challenges with overdetection and overtreatment.
• A need exists for more accurate diagnostic tools to improve prostate cancer management.

Purpose of the Study:

• To evaluate the potential of proenzyme PSA (proPSA) and its precursor forms, particularly [-2]proPSA, as next-generation diagnostic markers for prostate cancer.
• To assess the utility of [-2]proPSA in distinguishing between indolent and aggressive tumors and predicting disease progression.

Main Methods:

• Analysis of [-2]proPSA and related indices in patient cohorts.
• Comparison of [-2]proPSA performance against traditional PSA-based markers like %f-PSA and PSA density.
• Evaluation of [-2]proPSA as a predictive factor for pathological reclassification and future cancer development.

Main Results:

• [-2]proPSA demonstrates superior performance in distinguishing cancer from non-cancer and identifying aggressive tumors compared to existing PSA indices.
• Baseline [-2]proPSA-related indices are independent predictors of pathological reclassification in patients undergoing active surveillance.
• Retrospective studies suggest [-2]proPSA may predict future clinically manifested prostate cancer and aggressive tumor development.

Conclusions:

• Proenzyme PSA (proPSA), especially [-2]proPSA, represents a promising advancement in prostate cancer screening and management.
• ProPSA-related indices offer potential for a more refined risk classification system, enhancing detection of significant cancers while optimizing treatment and surveillance strategies.
• [-2]proPSA is poised to become a crucial marker in the future of prostate cancer care.